{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:08:55Z","timestamp":1792642135629,"version":"4.5.0"},"reference-count":100,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","internationaljournalofcardiology.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.ijcard.2016.11.174","type":"journal-article","created":{"date-parts":[[2016,11,9]],"date-time":"2016-11-09T14:15:18Z","timestamp":1478700918000},"page":"11-17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"special_numbering":"C","title":["Anticancer therapy-induced vascular toxicity: VEGF inhibition and beyond"],"prefix":"10.1016","volume":"227","author":[{"given":"Daniela","family":"Di Lisi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalinda","family":"Madonna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concetta","family":"Zito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Bronte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Badalamenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Parrella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Monte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Gabriele","family":"Tocchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Novo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2016.11.174_bb0005","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1517\/14740338.2015.986092","article-title":"Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy","volume":"14","author":"Bronte","year":"2015","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.ijcard.2016.11.174_bb0010","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.115.002661","article-title":"Cancer therapy-related cardiac dysfunction and heart failure: part 1: definitions, pathophysiology, risk factors, and imaging","volume":"9","author":"Bloom","year":"2016","journal-title":"Circ. Heart Fail."},{"key":"10.1016\/j.ijcard.2016.11.174_bb0015","doi-asserted-by":"crossref","first-page":"138148","DOI":"10.1155\/2015\/138148","article-title":"Recent advances on pathophysiology, diagnostic and therapeutic insights in cardiac dysfunction induced by antineoplastic drugs","volume":"2015","author":"Molinaro","year":"2015","journal-title":"Biomed. Res. Int."},{"issue":"1","key":"10.1016\/j.ijcard.2016.11.174_bb0020","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/cncr.29728","article-title":"Cardiovascular toxicity after antiangiogenic therapy in persons older than 65years with advanced renal cell carcinoma","volume":"122","author":"Jang","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.ijcard.2016.11.174_bb0025","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/CIRCRESAHA.109.206920","article-title":"Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics","volume":"106","author":"Cheng","year":"2010","journal-title":"Circ. Res."},{"key":"10.1016\/j.ijcard.2016.11.174_bb0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/eurjhf\/hfq213","article-title":"Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology","volume":"13","author":"Eschenhagen","year":"2011","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ijcard.2016.11.174_bb0035","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1093\/eurheartj\/ehs181","article-title":"Cancer drugs and the heart: importance and management","volume":"34","author":"Suter","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2016.11.174_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.cardfail.2016.04.008","article-title":"Models of heart failure based on the cardiotoxicity of anticancer drugs","author":"Mercurio","year":"2016","journal-title":"J. Card. Fail."},{"key":"10.1016\/j.ijcard.2016.11.174_bb0045","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1161\/CIRCRESAHA.113.300218","article-title":"Emerging paradigms in cardiomyopathies associated with cancer therapies","volume":"113","author":"Ky","year":"2013","journal-title":"Circ. Res."},{"issue":"Suppl. 2","key":"10.1016\/j.ijcard.2016.11.174_bb0050","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/00005344-200111002-00002","article-title":"A critical review of the role of endothelial factors in the pathogenesis of hypertension","volume":"38","author":"Schiffrin","year":"2001","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.ijcard.2016.11.174_bb0055","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1161\/HYPERTENSIONAHA.110.167015","article-title":"Flow-mediated dilation and cardiovascular event prediction does nitric oxide matter?","volume":"57","author":"Green","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.ijcard.2016.11.174_bb0060","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.3346\/jkms.2015.30.9.1213","article-title":"Endothelial dysfunction: clinical complications in cardiovascular disease and therapeutic approaches","volume":"30","author":"Park","year":"2015","journal-title":"J. Korean Med. Sci."},{"key":"10.1016\/j.ijcard.2016.11.174_bb0065","first-page":"25","article-title":"Angiogenesis - possibilities, problems and perspectives","volume":"61","author":"Kurzyk","year":"2015","journal-title":"Postepy Biochem."},{"key":"10.1016\/j.ijcard.2016.11.174_bb0070","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1093\/eurjhf\/hft008","article-title":"The emerging issue of cardiac dysfunction induced by antineoplastic angiogenesis inhibitors","volume":"15","author":"Tocchetti","year":"2013","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ijcard.2016.11.174_bb0075","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1538-7836.2008.03203.x","article-title":"Development of targeted angiogenic medicine","volume":"7","author":"Loges","year":"2009","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.ijcard.2016.11.174_bb0080","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrd2115","article-title":"Angiogenesis: an organizing principle for drug discovery?","volume":"6","author":"Folkman","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ijcard.2016.11.174_bb0085","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1161\/CIRCULATIONAHA.110.957332","article-title":"Vascular endothelial growth factor-B acts as a coronary growth factor in transgenic rats without inducing angiogenesis, vascular leak, or inflammation","volume":"122","author":"Bry","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2016.11.174_bb0090","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1161\/CIRCRESAHA.109.197830","article-title":"Activated forms of VEGF-C and VEGF-D provide improved vascular function in skeletal muscle","volume":"104","author":"Anisimov","year":"2009","journal-title":"Circ. Res."},{"key":"10.1016\/j.ijcard.2016.11.174_bb0095","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/cvr\/cvp270","article-title":"VEGF receptor switching in heart development and disease","volume":"84","author":"Madonna","year":"2009","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ijcard.2016.11.174_bb0100","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1161\/CIRCULATIONAHA.115.018347","article-title":"Vascular toxicities of cancer therapies: the old and the new - an evolving avenue","volume":"133","author":"Herrmann","year":"2016","journal-title":"Circulation"},{"issue":"Suppl. 18","key":"10.1016\/j.ijcard.2016.11.174_bb0105","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1200\/jco.2007.25.18_suppl.4136","article-title":"Serious arterial thromboembolic events (sATE) in patients (pts) with metastatic colorectal cancer (mCRC) treated with bevacizumab (BV): results from the BRiTE registry","volume":"25","author":"Sugrue","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 1","key":"10.1016\/j.ijcard.2016.11.174_bb0110","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/01.cad.0000361534.44052.c5","article-title":"Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib","volume":"21","author":"Mena","year":"2010","journal-title":"Anti-Cancer Drugs"},{"issue":"8","key":"10.1016\/j.ijcard.2016.11.174_bb0115","doi-asserted-by":"crossref","first-page":"966","DOI":"10.2174\/09298673113209990234","article-title":"Targeted therapies in hepatocellular carcinoma","volume":"21","author":"Bronte","year":"2014","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ijcard.2016.11.174_bb0120","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1517\/14740338.2013.788642","article-title":"Cardiovascular toxicity of tyrosine kinase inhibitors","volume":"12","author":"Mouhayar","year":"2013","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.ijcard.2016.11.174_bb0125","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1517\/14656566.2010.496453","article-title":"Sorafenib: a clinical and pharmacologic review","volume":"11","author":"lyer","year":"2010","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.ijcard.2016.11.174_bb0130","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1200\/JCO.2008.21.6994","article-title":"Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma","volume":"28","author":"Hutson","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijcard.2016.11.174_bb0135","article-title":"Rapid and fatal acute heart failure induced by pazopanib","author":"Marcke","year":"2015","journal-title":"BMJ Case Rep."},{"key":"10.1016\/j.ijcard.2016.11.174_bb0140","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S1470-2045(13)70093-7","article-title":"Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial","volume":"14","author":"Motzer","year":"2013","journal-title":"Lancet Oncol."},{"issue":"34","key":"10.1016\/j.ijcard.2016.11.174_bb0145","doi-asserted-by":"crossref","first-page":"35589","DOI":"10.18632\/oncotarget.5853","article-title":"What links BRAF to the heart function? New insights from the cardiotoxicity of BRAF inhibitors in cancer treatment","volume":"6","author":"Bronte","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ijcard.2016.11.174_bb0150","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","article-title":"Cabozantinib in progressive medullary thyroid cancer","volume":"31","author":"Elisei","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijcard.2016.11.174_bb0155","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.2217\/fon.15.119","article-title":"Should vascular effects of newer treatments be addressed more completely?","volume":"11","author":"Yang","year":"2015","journal-title":"Future Oncol."},{"key":"10.1016\/j.ijcard.2016.11.174_bb0160","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/leu.2013.69","article-title":"Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis","volume":"27","author":"Giles","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.ijcard.2016.11.174_bb0165","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2016.11.174_bb0170","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1161\/CIRCULATIONAHA.111.079921","article-title":"Pulmonary arterial hypertension in patients treated by dasatinib","volume":"125","author":"Montani","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2016.11.174_bb0175","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1038\/sj.bjc.6603813","article-title":"Mechanisms of adverse effects of anti-VEGF therapy for cancer","volume":"96","author":"Kamba","year":"2007","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ijcard.2016.11.174_bb0180","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ejca.2009.11.001","article-title":"VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management","volume":"46","author":"Izzedine","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ijcard.2016.11.174_bb0185","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1161\/HYPERTENSIONAHA.112.196774","article-title":"Management of antiangiogenic therapy-induced hypertension","volume":"60","author":"De Jesus-Gonzalez","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.ijcard.2016.11.174_bb0190","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1161\/CIRCULATIONAHA.110.992230","article-title":"Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension","volume":"124","author":"Nazer","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2016.11.174_bb0195","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1126\/science.277.5323.242","article-title":"Pericyte loss and microaneurysm formation in PDGF-B-deficient mice","volume":"277","author":"Lindahl","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.ijcard.2016.11.174_bb0200","doi-asserted-by":"crossref","first-page":"187ra69","DOI":"10.1126\/scitranslmed.3005066","article-title":"Coronary microvascular pericytes are the cellular target of sunitinib malate-induced cardiotoxicity","volume":"5","author":"Chintalgattu","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ijcard.2016.11.174_bb0205","doi-asserted-by":"crossref","first-page":"384","DOI":"10.3389\/fonc.2014.00384","article-title":"The role of notch in the cardiovascular system: potential adverse effects of investigational notch inhibitors","volume":"4","author":"Rizzo","year":"2015","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ijcard.2016.11.174_bb0210","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1016\/j.bcp.2010.07.010","article-title":"Inflammation dysregulates Notch signaling in endothelial cells: implication of Notch2 and Notch4 to endothelial dysfunction","volume":"80","author":"Quillard","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ijcard.2016.11.174_bb0215","article-title":"Cancer therapy induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies","volume":"3","author":"Shalkey-Hahn","year":"2014","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.ijcard.2016.11.174_bb0220","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1093\/eurheartj\/ehv132","article-title":"Cardiac endothelium-myocyte interaction: clinical opportunities for new heart failure therapies regardless of ejection fraction","volume":"36","author":"Lim","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2016.11.174_bb0225","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1161\/01.CIR.0000013839.41224.1C","article-title":"Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1\u03b2 and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity","volume":"105","author":"Sawyer","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2016.11.174_bb0230","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/nrc2106","article-title":"Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition","volume":"7","author":"Force","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ijcard.2016.11.174_bb0235","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1161\/CIRCRESAHA.109.205906","article-title":"The vulnerability of the heart as a pluricellular paracrine organ: lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy","volume":"106","author":"De Keulenaer","year":"2010","journal-title":"Circ. Res."},{"key":"10.1016\/j.ijcard.2016.11.174_bb0240","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1093\/eurjhf\/hfr165","article-title":"Detection, monitoring, and management of trastuzumab-induced left ventricular dysfunction: an actual challenge","volume":"14","author":"Tocchetti","year":"2012","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ijcard.2016.11.174_bb0245","doi-asserted-by":"crossref","first-page":"R35","DOI":"10.1186\/bcr1523","article-title":"Anti-erbB2 treatment induces cardiotoxicity by interfering with cell survival pathways","volume":"8","author":"Pugatsch","year":"2006","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.ijcard.2016.11.174_bb0250","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2217\/fca.11.54","article-title":"Cardio-oncology in targeting the HER receptor family: the puzzle of different cardiotoxicities of HER2 inhibitors","volume":"7","author":"Albini","year":"2011","journal-title":"Futur. Cardiol."},{"key":"10.1016\/j.ijcard.2016.11.174_bb0255","doi-asserted-by":"crossref","first-page":"19469","DOI":"10.1074\/jbc.M600399200","article-title":"Role of neuregulin-1\/ErbB2 signaling in endothelium-cardiomyocyte cross-talk","volume":"281","author":"Lemmens","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijcard.2016.11.174_bb0260","doi-asserted-by":"crossref","first-page":"12268","DOI":"10.3390\/ijms131012268","article-title":"Molecular mechanisms of cardiotoxicity induced by ErbB receptor inhibitor cancer therapeutics","volume":"13","author":"Hervent","year":"2012","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ijcard.2016.11.174_bb0265","first-page":"1147","article-title":"Endothelial dysfunction as a determinant of trastuzumab mediated cardiotoxicity in patients with breast cancer","volume":"1152","author":"Sandoo","year":"2014","journal-title":"Anticancer Res."},{"issue":"3","key":"10.1016\/j.ijcard.2016.11.174_bb0270","first-page":"70","article-title":"Trastuzumab-induced cardiac dysfunction: a\u2018dual-hit\u2019","volume":"16","author":"Zeglinski","year":"2011","journal-title":"Exp. Clin. Cardiol."},{"key":"10.1016\/j.ijcard.2016.11.174_bb0275","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1053\/j.seminoncol.2013.01.008","article-title":"Strategies to prevent and treat cardiovascular risk in cancer patients","volume":"40","author":"Cardinale","year":"2013","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.ijcard.2016.11.174_bb0280","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ctrv.2011.09.002","article-title":"Endothelial vascular toxicity from chemotherapeutic agents: preclinical evidence and clinical implications","volume":"38","author":"Soultati","year":"2012","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.ijcard.2016.11.174_bb0285","first-page":"267","article-title":"The anti-cancer drug, doxorubicin, causes oxidant stress induced endothelial dysfunction","volume":"2006","author":"Wolf","year":"1760","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ijcard.2016.11.174_bb0290","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1056\/NEJMcibr1214975","article-title":"Anthracyclines and heart failure","volume":"368","author":"Sawyer","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2016.11.174_bb0295","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1517\/14740338.2011.589834","article-title":"Anthracycline cardiotoxicity","volume":"11","author":"Menna","year":"2012","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.ijcard.2016.11.174_bb0300","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.redox.2013.01.014","article-title":"Teaching the basics of redox biology to medical and graduate students: oxidants, antioxidants and disease mechanisms","volume":"1","author":"Kalyanaraman","year":"2013","journal-title":"Redox Biol."},{"key":"10.1016\/j.ijcard.2016.11.174_bb0305","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1126\/science.6093249","article-title":"Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II","volume":"226","author":"Tewey","year":"1984","journal-title":"Science"},{"key":"10.1016\/j.ijcard.2016.11.174_bb0310","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0167-4781(92)90050-A","article-title":"Different patterns of gene expression of topoisomerase II isoforms in differentiated tissues during murine development","volume":"1132","author":"Capranico","year":"1992","journal-title":"Biochim. Biophys. Acta Gene Struct. Expr."},{"key":"10.1016\/j.ijcard.2016.11.174_bb0315","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1038\/nm.2919","article-title":"Identification of the molecular basis of doxorubicin-induced cardiotoxicity","volume":"18","author":"Zhang","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.ijcard.2016.11.174_bb0320","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/imj.12645","article-title":"Early and late changes in markers of aortic stiffness with breast cancer therapy","volume":"45","author":"Grover","year":"2015","journal-title":"Intern. Med. J."},{"key":"10.1016\/j.ijcard.2016.11.174_bb0325","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1002\/pbc.25547","article-title":"Arterial stiffness in childhood cancer survivors","volume":"62","author":"Krystal","year":"2015","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.ijcard.2016.11.174_bb0330","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.resp.2013.03.013","article-title":"Cardiotoxicity of cisplatin-based chemotherapy in advanced non-small cell lung cancer patients","volume":"1","author":"Demkow","year":"2013","journal-title":"Respir. Physiol. Neurobiol."},{"key":"10.1016\/j.ijcard.2016.11.174_bb0335","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1111\/j.1538-7836.2007.02788.x","article-title":"Chemotherapy induced thrombin generation via procoagulant endothelial microparticles is independent of tissue factor activity","volume":"5","author":"Lechner","year":"2007","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.ijcard.2016.11.174_bb0340","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/BF01744983","article-title":"Vitamin E prevents endothelial injury associated with cisplatin injection into the superior mesenteric artery of rats","volume":"10","author":"Ito","year":"1995","journal-title":"Heart Vessel."},{"key":"10.1016\/j.ijcard.2016.11.174_bb0345","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.ejca.2003.12.012","article-title":"Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer","volume":"40","author":"Nuver","year":"2004","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ijcard.2016.11.174_bb0350","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1002\/cncr.23389","article-title":"Cardiovascular risk in long-term survivors of testicular cancer","volume":"112","author":"Vaughn","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.ijcard.2016.11.174_bb0355","first-page":"482","article-title":"Coronary vasospasm induced by cytostatic drugs: Kounis syndrome seems to be the most likely culprit","volume":"54","author":"Mazarakis","year":"2013","journal-title":"Hell. J. Cardiol."},{"key":"10.1016\/j.ijcard.2016.11.174_bb0360","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1023\/A:1014059528046","article-title":"Gamma-hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor","volume":"4","author":"Basaki","year":"2001","journal-title":"Angiogenesis"},{"key":"10.1016\/j.ijcard.2016.11.174_bb0365","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1080\/02841860310004409","article-title":"Effects on probucol on endothelial damage by 5-fluorouracil","volume":"42","author":"Kinhult","year":"2003","journal-title":"Acta Oncol."},{"key":"10.1016\/j.ijcard.2016.11.174_bb0370","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1161\/01.ATV.0000030186.66672.36","article-title":"Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor\/vascular endothelial growth factor receptor pathway in cancer patients","volume":"22","author":"Kuenen","year":"2002","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ijcard.2016.11.174_bb0375","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/02841860802314720","article-title":"Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis","volume":"48","author":"Zhu","year":"2009","journal-title":"Acta Oncol."},{"key":"10.1016\/j.ijcard.2016.11.174_bb0380","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1200\/JCO.2007.11.0106","article-title":"Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility","volume":"25","author":"Telli","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijcard.2016.11.174_bb0385","first-page":"1191","article-title":"Inhibition of endothelial cell function in vitro and angiogenesis in vivo by docetaxel (Taxotere): association with impaired repositioning of the microtubule organizing center","volume":"1","author":"Hotchkiss","year":"2002","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ijcard.2016.11.174_bb0390","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/FJC.0b013e3181d263f7","article-title":"Paclitaxel potentiates inflammatory cytokine induced prothrombotic molecules in endothelial cells","volume":"55","author":"Wood","year":"2010","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.ijcard.2016.11.174_bb0395","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/toxsci\/kfq189","article-title":"Primary endothelial damage is the mechanism of cardiotoxicity of tubulin-binding drugs","volume":"117","author":"Mikaelian","year":"2010","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.ijcard.2016.11.174_bb0400","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0022-3565(25)38491-0","article-title":"Cyclophosphamide-induced lung toxicity: mechanism of endothelial cell injury","volume":"268","author":"Kachel","year":"1994","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ijcard.2016.11.174_bb0405","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/BF00252982","article-title":"Severe vascular toxicity associated with vinblastine, bleomycin, and cisplatin chemotherapy","volume":"19","author":"Samuels","year":"1987","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ijcard.2016.11.174_bb0410","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/ehjci\/jet123","article-title":"Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography","volume":"14","author":"Lancellotti","year":"2013","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"10.1016\/j.ijcard.2016.11.174_bb0415","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/1097-0142(197801)41:1<130::AID-CNCR2820410121>3.0.CO;2-X","article-title":"Radiation-induced carotid artery disease","volume":"41","author":"Silverberg","year":"1978","journal-title":"Cancer"},{"key":"10.1016\/j.ijcard.2016.11.174_bb0420","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1161\/01.ATV.19.6.1387","article-title":"Ionizing radiation accelerates aortic lesion formation in fat-fed mice via SOD-inhibitable processes","volume":"19","author":"Tribble","year":"1999","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ijcard.2016.11.174_bb0425","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2353\/ajpath.2006.050409","article-title":"Ionizing radiation accelerates the development of atherosclerotic lesions in ApoE\u2212\/\u2212 mice and predisposes to an inflammatory plaque phenotype prone to hemorrhage","volume":"168","author":"Stewart","year":"2006","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ijcard.2016.11.174_bb0430","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1177\/0003319713498298","article-title":"Cardiotoxicity and cancer therapy","volume":"65","author":"Vasiliadis","year":"2014","journal-title":"Angiology"},{"key":"10.1016\/j.ijcard.2016.11.174_bb0435","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/1475-2840-12-155","article-title":"Preclinical atherosclerosis and metabolic syndrome increase cardio- and cerebrovascular events rate: a 20-year follow up","volume":"12","author":"Novo","year":"2013","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.ijcard.2016.11.174_bb0440","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.atherosclerosis.2010.01.019","article-title":"Preclinical carotid atherosclerosis enhances the global cardiovascular risk and increases the rate of cerebro- and cardiovascular events in a five-year follow-up","volume":"211","author":"Novo","year":"2010","journal-title":"Atherosclerosis"},{"issue":"115","key":"10.1016\/j.ijcard.2016.11.174_bb0445","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1161\/CIRCULATIONAHA.106.628875","article-title":"Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis","volume":"30","author":"Lorenz","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2016.11.174_bb0450","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1093\/eurheartj\/ehl254","article-title":"Expert consensus document on arterial stiffness: methodological issues and clinical applications","volume":"27","author":"Laurent","year":"2006","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2016.11.174_bb0455","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1161\/CIRCIMAGING.113.000899","article-title":"Cardiac MRI in the assessment of cardiac injury and toxicity from cancer chemotherapy: a systematic review","volume":"6","author":"Thavendiranathan","year":"2013","journal-title":"Circ. Cardiovasc. Imaging"},{"issue":"Suppl. 1","key":"10.1016\/j.ijcard.2016.11.174_bb0460","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1097\/01.hjh.0000467649.08167.c3","article-title":"Possible role of arterial function in cancer treatment targeting vascular endothelial growth factor receptor oncologic response","volume":"33","author":"Vallerio","year":"2015","journal-title":"J. Hypertens."},{"key":"10.1016\/j.ijcard.2016.11.174_bb0465","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/ajh\/hpv077","article-title":"Effects of cancer therapy targeting vascular endothelial growth factor receptor on central blood pressure and cardiovascular system","volume":"29","author":"Moreo","year":"2016","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.ijcard.2016.11.174_bb0470","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1200\/JCO.2009.23.8527","article-title":"Aortic stiffness increases upon receipt of anthracycline chemotherapy","volume":"28","author":"Chaosuwannakit","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijcard.2016.11.174_bb0475","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/pbc.24829","article-title":"Signs of early sub-clinical atherosclerosis in childhood cancer survivors","volume":"61","author":"Dengel","year":"2014","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.ijcard.2016.11.174_bb0480","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1093\/ehjci\/jeu192","article-title":"Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"15","author":"Plana","year":"2014","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"10.1016\/j.ijcard.2016.11.174_bb0485","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2174\/1574890110999150604114127","article-title":"Anti-VEGF anticancer drugs: mind the hypertension","volume":"9","author":"Katsi","year":"2014","journal-title":"Recent Pat. Cardiovasc. Drug Discov."},{"key":"10.1016\/j.ijcard.2016.11.174_bb0490","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1161\/CIRCULATIONAHA.104.532960","article-title":"Endothelial beta3-adreno- receptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol","volume":"112","author":"Dessy","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2016.11.174_bb0495","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ahj.2011.10.018","article-title":"Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors","volume":"163","author":"Steingart","year":"2012","journal-title":"Am. Heart J."},{"issue":"Suppl. 7","key":"10.1016\/j.ijcard.2016.11.174_bb0500","article-title":"Cardiovascular toxicity induced by chemotherapy,targeted agents and radiotherapy: ESMO clinical practice guidelines","volume":"23","author":"Curigliano","year":"2012","journal-title":"Ann. Oncol."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016752731633635X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016752731633635X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T07:26:43Z","timestamp":1749713203000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016752731633635X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":100,"alternative-id":["S016752731633635X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2016.11.174","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anticancer therapy-induced vascular toxicity: VEGF inhibition and beyond","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2016.11.174","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}